#Germany #Spatial Biology #Oberkochen #Revolune GmbH #immunofluorescence

Introduction

Revolune GmbH, a newly established company, is set to make waves in the life sciences arena by facilitating a deeper understanding of complex biological systems. Officially launched on April 15, 2026, the company focuses on advancing spatial biology through innovative multiplex immunofluorescence (mIF) solutions. These reagents aim to streamline tissue analysis workflows, providing reliable and efficient results critical for translational and biopharmaceutical research.

The Need for Streamlined Solutions

In the modern biomedical research landscape, the analysis of biomarkers in spatial resolution is essential for elucidating the intricate biology of tissues and expediting therapeutic development. However, current multiplex tissue workflows are often burdened with significant technical complexity, operational frictions, and reproducibility challenges that hinder their wider adoption. Revolune was founded specifically to address these barriers by creating reagents that bring clarity, speed, and reliability to multiplex tissue analysis.

A Vision for Clarity

“At Revolune, our mission is straightforward—illuminate what matters,” states Florian Leiss, CEO of Revolune. “Researchers need tools that allow them to concentrate on biological questions rather than workflow complexities. We are committed to enabling spatial biology with robust, scalable, and practical technologies for real-world laboratory environments.” The company's initial focus lies on multiplex immunofluorescence reagents, offering researchers the ability to visualize multiple biomarkers within the architecture of intact tissues, yielding deeper spatial insights for translational and biopharmaceutical applications.

Focus on Reliability and Adoption

What sets Revolune apart is its emphasis on workflow reliability, ease of adoption, and confidence in experimental outputs. The company aims to help scientists establish reproducible multiplex analyses with the same simplicity as immunohistochemistry workflows. This approach is critical in a field where data integrity and reproducibility are paramount.

Experienced Leadership

Florian Leiss, bringing extensive expertise in spatial biology and technological development within the life sciences sector, leads Revolune. Prior to its founding, he spearheaded strategic initiatives within the ZEISS ecosystem aimed at advancing spatial biology workflows for biopharmaceutical applications. His work in translating biomarker analysis through imaging into scalable and actionable solutions paved the way for creating Revolune as an independent spin-out. This positions the company as a dedicated platform to tackle key bottlenecks in spatial biology workflows.

Expansion and Future Prospects

Joining Leiss at Revolune is Michaeli Deli, who has been appointed as Chief Financial Officer to support the strategic growth and operational development of the company as it enters a new phase of expansion. Alongside its launch, Revolune is introducing an early-access program, inviting selected research groups to explore the company's multiplex immunofluorescence technologies and collaborate on the development of next-generation spatial biology workflows. For more information, visit Revolune's website to stay updated on the latest advancements and opportunities in spatial biology.

Conclusion

Revolune GmbH is poised to reshape the landscape of spatial biology through its advanced solutions in multiplex immunofluorescence. By addressing challenges in tissue analysis and facilitating higher-quality research, Revolune not only aims to enhance scientific understanding but also to accelerate therapeutic discoveries. This innovative approach makes it a noteworthy player in the life sciences sector, promising to deliver essential insights into the complex interplay of biological structures in health and disease.